Table 1.
Patient baseline and tumor characteristics
| Patient baseline and tumor characteristics | |
|---|---|
| Sex, n (%) | |
| Female | 11 (61.1) |
| Male | 7 (38.9) |
| Age, years | |
| Median | 74 (range 49–92) |
| Weight, kg | |
| Median | 72 (range 50–145) |
| Height, m | |
| Median | 1.68 (range 1.50–1.85) |
| ECOG (0–5) | |
| 0 | 18 (100) |
| Skin type (Fitzpatrick) | |
| 2 | 15 (83.3) |
| 3 | 3 (16.7) |
| Histopathological BCC subtype, n (%) | |
| Non-infiltrative | 9 (50.0) |
| Infiltrative | 9 (50.0) |
| BCC ulceration n (%) | |
| Yes | 9 (50.0) |
| No | 9 (50.0) |
| BCC localization, n (%) | |
| Head and neck | 13 (72.2) |
| Lower extremities | 2 (11.1) |
| Trunk | 3 (16.7) |
| Longest tumor diameter, cm | |
| Median | 1.4 (range 0.7–13.7) |
| Recurrent BCC, n (%) | |
| Yes | 2 (11.1) |
| No | 16 (88.9) |
| Previous BCC surgery, n (%) | |
| Yes | 2 (11.1) |
| No | 16 (88.9) |
| Previous BCC therapy, n (%) | |
| Yes | 5 (27.8) |
| No | 13 (72.2) |
| Previous BCC, n (%) | |
| Yes | 3 (16.7) |
| No | 15 (83.3) |
| Previous HSV infection, n (%) | |
| Yes | 12 (66.7) |
| No | 6 (33.3) |
| Previous HSV lesion localization, n (%) | |
| Oral | 11 (61.1) |
| Oral and genital | 1 (5.6) |
| NA | 6 (33.3) |
| Serum HSV IgG, n (%) | |
| Negative | 1 (5.6) |
| Positive | 17 (94.4) |
Percentages are based on the number of valid values (n). Included are s.d., Eastern Cooperative Oncology Group (ECOG) performance status, BCC and HSV.